Research
Hormonal
The combination of Semaglutide and VLCD provoked greater improvements in pancreatic beta-cell function than VLCD alone.
Combining Semaglutide with VLCD may enhance pancreatic function in T2D management.
StrongSupportsmedium confidence
Insulin first phase response during IVGTT increased in SEM and COMB, and this increase was significantly greater in COMB than VLCD.
Why this rating
Based on the randomized controlled trial design mentioned in the abstract.
Source
Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus
Oluwaseun Anyiam et al. · Clinical Nutrition · 2024
DOI 10.1016/j.clnu.2024.06.034
otherCited 31×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →